Frontiers in Anti-Cancer Drug Discovery: Volume 5

Table of Contents

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

Usage Rules:

Disclaimer:

Limitation of Liability:

General:

PREFACE

Nutrition, Nutraceutics and Cancer

Abstract

Introduction

Lifestyle as the primary factor for preventing cancer: from diet and physical activity to nutritional status

Diet

Physical Activity

Nutritional Status

Nutritional approaches, functional foods and nutraceuticals: molecular pathways, scientific evidence and potential applications within cancer therapy

Energy Restriction

Omega-3 Fatty Acids [72-83]

Sulforaphane

Lycopene

Antioxidants

Polyphenols (Brief Examples)

Microbiota [125-134]

Conclusion

ACKNOWLEGDEMENTS

CONFLICT OF INTEREST

References

Natural Food Products, Rich in Lycopene and Beta-Carotene, or Dietary Supplements for Cancer Prevention

Abstract

INTRODUCTION

Role of Natural Plant Food Products, Rich in Bioactive Substances, in Cancer Prevention

Bioactive Food Compounds in the Prevention of Chronic Diseases

Epidemiologic Evidence for a Relation between Food and Chronic Diseases

Lycopene and Β-carotene as cancer preventive phytonutrients

The Antioxidant Effects of Lycopene

Role of Lycopene in the Prevention of Cancer

Lycopene in Chemoprevention of Prostate Cancer

Βeta-Carotene in Cancer Prevention

Whole Foods or Dietary Supplements in Cancer Prevention?

Health-Promoting Food Ingredients, Sourced from Plants

Health Benefits of Fruit and Vegetables from Additive and Synergistic Combinations of Phytochemicals

Dose Issues Related to Dietary Supplements

Functional Foods and/or Dietary Supplements in Cancer Prevention

Food Ingredients for Promoting Health and Functional Food Processing

CONCLUSION

ACKNOWLEGDEMENTS

CONFLICT OF INTEREST

REFERENCES

Concepts of Anticancer Treatment and Pharmacogenomics in Cancer Treatments

Abstract

CANCER BACKGROUND

CHEMOTHERAPY TREATMENT BACKGROUND

CHEMOTHERAPY DISCOVERY AND DEVELOPMENT

IS ANTICANCER DRUG THERAPY DEVELOPMENT HEADING IN THE CORRECT DIRECTION?

PHARMACOGENETICS

PHARMACOGENOMICS

THE MAIN AIMS OF PHARMACOGENOMICS

The First Aim: Personalizing Medicine

The Second Aim: Drugs Affecting Gene Expression

The Third Aim: Detection of New Targets for Future Drugs

CANCER PHARMACOGENOMICS

GENERAL CONSIDERATION IN CANCER PHARMACOGENOMICS

Pharmacokinetics in Cancer Pharmacogenomic Drug Metabolism

Phase I Enzymes

Phase II Enzymes

Pharmacodynamics in Cancer Pharmacogenomics-Drug Targets

Drug Transports Pumps (Drug Efflux Pumps)

Mitoxantrone Resistance Protein (MXR)

Multiple Drug Resistance 1 (P-Glycoprotein)

INCIDENCE OF GENETIC VARIATION IN THE MIDDLE OF CANCER PROGRESSION

Hematological Tumors

Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia (AML)

Chronic Lymphocytic Leukemia (CLL)

Chronic Myelogenous Leukemia (CML)

Solid Tumors

Breast Cancer

Colorectal Cancer

Prostate Cancer

IMPORTANCE OF FOCUSING ON CANCER PATIENTS GENE EXPRESSION PROFILE

APPLICATION OF PHARMACOGENOMICS IN THE DEVELOPMENT OF CHEMOTHERAPY AGENTS

PROMISES AND PROOFS OF PHARMACOGENOMICS IN THE SUCCESS OF CHEMOTHERAPY

Pyrimidine Analogs 5-Flurouracil (5-FU)

Topoisomerase I Inhibitors (Irinotecan)

Purine Analogs (6-Mercaptopurine and 6-Thioguanine)

Folic Acid Antimetabolites (Methotrexate)

Selective Estrogen Receptor Modulators (Tamoxifen)

Taxanes (Paclitaxel and Docetaxel)

Platinum Agents

Alkylating Agents (Cyclophosphamide)

APPLICATION OF PHARMACOGENOMICS STUDIES IN PREDICTING AND/OR OVERCOMING CHEMOTHERAPY SIDE EFFECTS

PERSONALIZING CHEMOTHERAPY TREATMENT

A-Personalizing Breast Cancer Treatment

B-Personalizing Bladder Cancer Treatment

C-Personalizing Colon Cancer Treatment

PERSONALIZING ANTICANCER THERAPY BASED ON TUMOR ONCOGENIC PATHWAY MARKERS

DISCOVERIES IN MOLECULAR TARGETED THERAPIES USED FOR CANCER TREATMENT

A-Induction of Apoptosis and Inhibition of Anti-Apoptosis

B-Anti-Metastatic Treatment

PHARMACIST AND PHARMACOGENOMICS ROLE IN PERSONALIZING CHEMOTHERAPY TREATMENT

CONCLUSION

ACKNOWLEDGeMENTS

CONFLICT OF INTEREST

REFERENCES

In Silico Classification Models for Anticancer Drugs

Abstract

1.. INTRODUCTION

2. IN SILICO TECHNIQUES IN ANTI-CANCER DRUG DESIGN

CURRENT AND FUTURE PERSPECTIVE

ACKNOWLEGDEMENTS

CONFLICT OF INTEREST

REFERENCES

Cancer Stem Cells, Models, Drugs and Future Prospective

Abstract

Cancer stem cells (CSCS); Definition, Theory and Pioneer

Isolation of CSCS

In vitro & In vivo model of CSCS

Drugs selective for CSCS

New challenges and future prospective

ACKNOWLEGDEMENTS

CONFLICT OF INTEREST

References

Cancer Drugs Targeting the p53 Regulatory Machinery

Abstract

Introduction

Cellular responses upon P53 activation

The P53 regulatory pathway in vertebrates

P53-MDM2 interactions

Structural Features of p53 and MDM2

p53 Activation and Inactivation

Drugs targeting P53 directly

Gene Therapy

Retroviruses

Adenoviruses

Strategies Targeting Cytoplasmic p53

Pharmacological activation of P53

Drugs Targeting p53-MDM2 Interaction

Targeting Histone Deacetylases

Reactivating Mutant p53

The Use of Single Chain Antibody Fragments Targeting Mutant p53

Potential Neoadjuvant Therapy Drugs

The retinoblastoma binding protein 6 family as a potential drug target

Conclusion

ACKNOWLEGDEMENTS

CONFLICT OF INTEREST

References

Designing of Drug Molecules for Reversing PGlycoprotein (P-gp) Mediated Drug Resistance in Cancer Cells

Abstract

INTRODUCTION

BASIC MECHANISM IN CANCER MDR

DRUG TARGETS IDENTIFIED TO SENSITIZE THE MULTIDRUG RESISTANT (MDR) CANCER CELLS

REASONS FOR THE FAILURE OF PREVIOUS CLINICAL TRIALS

MDR MODIFYING AGENTS

Most Studied Descriptor-pKa and Lipophilicity

VARIOUS P-GP INHIBITORS STUDIED TO OVERCOME MDR IN CANCER

Nanodrug Delivery to Overcome MDR in Cancer Cells

Other Strategies to Overcome MDR in Cancer Cells

Mathematical Perspective of Drug Resistance

Acridones as MDR Reversing Agents

Our Research Findings on Acridones as MDR Modulators

Various Reasons for the Lack of Clinical Success of MDR Inhibitors in Cancer

Clinical Studies of MDR Drugs: Problems and Design Issues

Future Prospects for the Design and/or Discovery of Modulators of Multidrug Resistance in Cancer

Structure Activity Relationships (SAR) Among the Various P-Glycoprotein Modulators

Drug-Binding Sites on P-Glycoprotein

CONCLUSION

ACKNOWLEGDEMENTS

CONFLICT OF INTEREST

REFERENCES

Targeting Potassium Channels for Drug Delivery to Brain Tumors

Abstract

Introduction

Ion Channels in Brain Tumors

Potassium Channels

BKCa Channels

Inwardly Rectifying K+ Channels (Kir)

Ether `A Go-Go K+ Channels

Chloride Channels

Calcium Channels

Sodium Channels

Future Therapeutic Targets

Ion Channels on BTB

Blood-Brain Barrier (BBB) vs Blood Brain-Tumor Barrier (BTB)

Interaction of Brain Tumor Microenvironment with Capillary Endothelial Cells

BKCa and KATP channels in Brain

Biochemical Modulation to Bypass BTB

Targeting Ion Channels for Delivering Imaging Agents and Therapeutics

Drug Delivery to Brain Tumors: Opportunities

Modification of BTB Permeability in the Leading Glioma Edges for Better Detection

Summary

ACKNOWLEGDEMENTS

CONFLICT OF INTEREST

References

The Developing Role of Sorafenib in the Management of Hepatocellular Carcinoma

Abstract

INTRODUCTION

THE IDENTITY OF SORAFENIB

Mechanism of Action

Dosage and Toxicity

USE OF SORAFENIB – STRATEGIES INVOLVED

Officially Approved Uses of Sorafenib

Sorafenib Monotherapy

Sorafenib and Resection

Sorafenib and Liver Transplantation

Sorafenib as Neoadjuvant Treatment prior to Liver Transplantation

Sorafenib as Adjuvant Treatment after Liver Transplantation

Sorafenib and Locoregional Treatments

Sorafenib Combined Use with other Agents

Sorafenib and mTOR Inhibitors

Sorafenib and MEK Inhibitors

Sorafenib and PI3K/AKT

Sorafenib and JAK/STAT

Sorafenib and Hypoxia-Inducible Factor (HIF)-1a

Alternatives to Sorafenib

CONCLUSION

ACKNOWLEGDEMENTS

CONFLICT OF INTEREST

REFERENCES

Frontiers in Anti-Cancer Drug Discovery

Volume 5

Editor

Atta-ur-Rahman, FRS

Honorary Life Fellow

Kings College

University of Cambridge

UK

Co-Editor

M. Iqbal Choudhary

H.E.J. Research Institute of Chemistry

International Center for Chemical and Biological Sciences

University of Karachi

Pakistan

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (Work). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].

Usage Rules:

All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.

You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:

25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.

25 pages only from the Work can be printed every 7 days.

3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided as is without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).

Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

PREFACE

Prof. Atta-ur Rahman, FRSProf. M. Iqbal Choudhary

Honorary Life Fellow

Kings College

University of Cambridge

UK

H.E.J. Research Institute of Chemistry

International Center for Chemical and Biological Sciences

University of Karachi

Pakistan

Cancer remains a leading cause of death, despite decades of fundamental and applied research in this field. However, early diagnosis, better understanding of disease processes, preventive strategies, and development of new classes of anti-cancer drugs have contributed to improving the survival rate and quality of lives of cancer patients.

Volume 5 of Frontiers in Anti-Cancer Drug Discovery contains well written comprehensive reviews of various aspects of cancer biology, prevention and drug designing. These articles, contributed by leading experts, reflect the diversity and complexity of the research field, and where it stands today. This must read eBook is a comprehensive treatise of the state-of-the-art in cancer research.

The first two reviews in this volume relate to diet and its relationship to the on-set of cancer. Diet can be a part of the problem, or part of the solution. It can cause certain cancers, and also prevent cancers, depending on what you eat. Cancer prevention by using dietary agents is now one of the most active areas of research.

Gabriela Gutiérrez-Salmeán et al. review the various dietary components which are associated with increased risk of certain cancers. The authors have provided an interesting commentary on various classes of dietary agents, such as antioxidants, omega-3 fatty acids, and polyphenols which are perceived as cancer chemopreventive agents. The pitfalls of their use as adjuvants and the non-conclusive clinical data, is also vigorously debated.

Atanasova and Gatseva have contributed a comprehensive review of the results of various epidemiological studies on the reduced risk of cancers with the consumption of certain functional foods, rich in bioactive substances. The role of various types of carotenoids in cancer prevention is extensively reviewed in this article. Evidences are presented that antioxidant micronutrients of natural origin are far superior in providing cancer prevention than their synthetic analogs.

Bassam Abdul Rasool Hassan has reviewed the pivotal role of pharmacogenomics in cancer treatment. It is now well established that genetics plays a key role in the on-set and progression of cancer, as well as the therapeutic outcome. Intra-individual genetic variations directly affect the drug response. Therefore pharmacogenomics is increasingly used in cancer treatment. This interesting review narrates the role of pharmacogenomics in drug selection, dosage, duration of treatment, and safety and toxicity.

In silico methods continue to play an important role in drug discovery and optimization. Dutt and Madan review the systematic utilization of in silico approaches in accelerating drug discovery and designing drugs for cancer treatment. They have discussed the effectiveness of various in silico models, and machine learning techniques, employed for the development of novel anti-cancer agents.

Ali Zekri et al. uncover a novel aspect of cancer biology by reviewing the most recent literature on cancer stem cells (CSCs) as target for anti-cancer drugs. These cells are responsible for the heterogeneity of tumor mass, and are often resistant to standard cancer chemotherapies. The chapter highlights the importance of further studies in this exciting field.

The next three chapters focus on two key targets for anti-cancer drug discovery. Drug resistance in cancer cells is a growing threat to the effectiveness of current therapeutic regimen. Efflux pump p-glycoproteins (P-gp) play an important role in hindering cancer chemotherapy. Extensive research is being conducted targeting the p-glycoprotein efflux pump. The chapter by Mayur C. Yergeri describes the various classes of natural and synthetic compounds, which can selectively inhibit P-gp and other transporters.

Monde Ntwasa has contributed a review on small molecular activators of p53 regulatory machinery, which can serve as anti-cancer agents. p53 protein is down regulated or inactivated in many cancers, and factors which contribute to the inactivation of p53 protein can be targeted to upregulate its expression as a therapeutic strategy.

Ningaraj and Khaitan describe the role of ion channels [(Ca-dependent K+ channels (BKca) and ATJP-sensitive K+ (KATP) channels] in brain cancers which unfortunately have poor prognosis, and are often difficult to treat. They have presented the out-comes of their own work on BKca and KATP channels inhibitors which can enhance the delivery of antineoplastic drugs and imaging agents in cancer cells.

Agorastou and Tsoulfas have discussed the therapeutic potential of sorafenib, a multi-kinase inhibitor against Raf kinase, as a drug against hepatocellular carcinoma (HCC). Sorafenib can be used in different stages of cancer progression and apparently works as an anti-angiogenetic agent. The use of sorafenib, alone or in combination, and therapeutic outcomes against HCC are extensively reviewed.

This volume of the eBook series represents the results of a considerable amount of work by many eminent scholars. We wish to thank them all for their excellent contributions, and their commitment to complete the writing assignments in an efficient manner. We would also like to thank the excellent team of Bentham Science Publishers, especially Ms. Fariya Zulfiqar led by Mr. Mahmood Alam, Director Bentham Science Publishers, who deserve all appreciation.

Nutrition, Nutraceutics and Cancer

Gabriela Gutiérrez-Salmeán*, Alejandro Ríos-Hoyo, Huguette Ríos-Ontiveros, Ma José Cortés

Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, México

Abstract

Cancer is a leading cause of death worldwide. Although genetics certainly plays an important role, environmental factors -i.e., overall lifestyle, including diet, physical activity, and nutritional status, among others- are known to be triggering factors for the development of many types of cancer. Different dietary components have been associated with the risk of developing cancer; these include alcohol, red (processed) meat, and low-fiber diets. On the contrary, physical activity and the practice of frequent exercise, together with an energetically-restrictive dietary regimen appear to reduce the risk of neoplastic diseases. Moreover, specific substances within food have been considered to exert biologically active properties and thus have been considered as attractive candidates to be used not as a sole approach but -maybe- as coadjuvant agents during cancer therapy. Such nutraceuticals include: antioxidants, sulphoraphane, omega-3 fatty acids, lycopene, and polyphenols, among other. Even though preclinical and small clinical trials have shown promising evidence, it is still inconclusive, hence no actual dosage recommendations can yet be emitted. These open an interesting and urgent research field within Nutrition and Oncology.

Keywords: : Antioxidants, cancer, coadjuvant, diet, energy restriction, functional foods, lifestyle, nutrition, nutrition status, nutraceuticals, omega-3, physical activity, polyphenols, sulphoraphane.

* Corresponding Author Gabriela Gutiérrez-Salmeán: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Av. Universidad Anáhuac #46. Lomas Anáhuac. Huixquilucan, Estado de México, ZIP 52786, México; Tel: (52) (55) 5627 0210; E-mail: [email protected]

Introduction

Cancer is a leading cause of death worldwide. Although genetics and chronic exposure to certain specific agents (e.g., tobacco smoke, ionizing radiation, asbestos, arsenic, etc.) are considered as the primary risk factors within carcinogenesis, the overall lifestyle -including diet, physical activity, and nutritional status, among others- has been evidenced to play simultaneous and interrelated triggering roles for the development of many types of cancer.Nutrition, for its side, refers not only to the eating process, but instead to the series of physiologic events through which food is digested, absorbed, metabolized, and used by the body in order to maintain optimal health. Diet therapy, therefore, is not only important in order to prevent the development of disease -including cancer- but it is also of crucial importance during antineoplastic treatment of any patient as a well-nourished patient has a better overall prognosis in terms of oncologic response and survival, together with a decreased chance of presenting complications, toxicities, and cancer recurrence.

Moreover, the emerging field of pharmaconutrition and the use of functional foods and nutraceuticals (i.e., the use of specific foods or isolated nutrients aimed to give additional effects more than those given as energy or nutrimental value and often related to modulating health promotion and/or disease progression) have raised increasing interest in exploring the potential applicability of such agents, not as monotherapy, but as coadjuvant mediators of the primary treatment.

Due to the aforementioned, along this chapter, we present scientific evidence showing the relationship among diet, physical activity, nutrition status, and cancer; followed by a brief revision of specific dietary components under research due to their potential in the modulation of the carcinogenic process.

Lifestyle as the primary factor for preventing cancer: from diet and physical activity to nutritional status

Research has shown that up to 30% of cancers can be prevented through diet and regular physical activity, thus yielding a healthy weight -nutrition status-; therefore, lifestyle modifications could greatly contribute to a worldwide reduction in the cancer burden.

Diet

While other foods, nutraceuticals and dietary components that have been associated with a reduced cancer risk will be mentioned, herein we present quite the opposite: foods to avoid -better said, minimize consumption- as they have been linked with increased risk of tumorigenesis.

Alcohol. Chronic binge drinking has been recognized as an important risk factor for cancer -particularly of the digestive tract- for more than 100 years [1]; recently, it has also been associated to breast, liver, colon, and rectum cancers [2]. Studies have found that even light-drinking (i.e., ≤12.5 g/day) is associated with a 7% increase in the risk, whereas heavy drinking is associated with a 52% increased risk, compared with nondrinkers or occasional alcohol drinkers [3]. Although molecular mechanisms for alcohol’s increased risk in cancer initiation and progression have not been fully elucidated, some have been proposed, for example: the metabolism of ethanol into acetaldehyde also promotes oxidative stress, which in turn, may initiate/progress carcinogenesis due to the binding of free radicals to DNA and/or proteins hence promoting mutations. In addition, alcohol can activate proinflammatory pathways associated to tumorigenesis [4]. Finally, evidence also suggests that alcohol excessive intake also modulates epigenetics as it promotes aberrant DNA methylation -most likely through decreasing the main biological methyl donor, S-adenosylmethionine (SAMe), bioavailability- [5-6].

As with everything, there are two sides of a coin; regarding alcohol consumption and cancer, several observational studies have also evidenced that - opposite to excessive drinking- moderate alcohol intake (i.e., 1 or 2 glasses/day, for women and men, respectively) is associated with reduced overall morbidity and mortality. Nevertheless, it has not been established whether such health benefits are due to ethanol and/or other non-alcoholic components (e.g., polyphenols, as we will later discuss) [7].

Red Meat. Several observational studies have found a possibly increased relative risk of cancer (prostate, colorectal, hepatic, and esophageal, among others) in patients with high dietary consumption of meat [8{Pham, 2014 #711, 8-10].

It is worth mentioning that such association remains controversial as results have been inconsistent among studies and, moreover, there is a statistical difference when dividing all meat from processed meat. This may be explained by the fact that, with cooking and processing of meat and meat products [11], compounds like heterocyclic amines and nitrosamines and N-nitroso compounds -which exhibit carcinogen activity- are produced; moreover, smoking, grilling, and/or charcoal cookery yield pyrolysates (also carcinogenic and mutagenic activity) [12-14]. Other possible contributors to such increased risk are additives used in processed meat products, e.g., nitrites and nitrates; these have also been reported to exert genotoxicity thus carcinogen effects, mainly at the gastrointestinal level but also in lung and thyroid [15-18]. In fact, studies have reported a stronger association and higher risk for advanced prostate cancer in subjects with more frequent consumption of hamburgers, processed meat, grilled meat, and barbequed and well or very well done meat [19-21].

Yet another hypothesis states that regular meat consumption promotes chances in the colonic microbiota, enhancing the colonization and predominance of Bacteroidetes. These microorganisms synthesize menaquinones -vitamin K isoprenalogues- which have been proposed as initiators of redox cycling reactions that yield superoxide and hydrogen peroxide, i.e., powerful oxygen reactive species. Moreover, additional vitamin K1 metabolites, e.g., phylloquinone, which are both obtained from either microbiome or mixed within bile acids, have also been reported to enter into a redox cycle that yields superoxide. The latter may, in turn, rapidly react and oxidize proteins and/or fatty acids, starting a chain reaction that further contributes to oxidative stress and may form active carcinogens or tumor promotors, thus, may be considered as a risk factor for carcinogenesis [22-23].

Finally, meat consumption also increases fecal iron content (as meat contains it within haemoglobin). Heme iron has been proposed as a possible initiator and promoter of colon cancer as it enhances lipid peroxidation, mainly through Fenton reactions [24]. Furthermore, is has been recently proposed that intestinal microbiota could play a crucial role within iron-associated cancer pathogenesis as fecal lipoperoxidation markers (e.g., malondialdehyde) significantly decrease after antibiotic treatment. [25]

Summing up, despite the fact that reports are controversial and therefore no contending evidence has linked meat to cancer risk, all investigations consent to advice that red meat intake should be limited/minimized as such food might be associated with increased risk of carcinogenesis although prospective studies and experimental research are indeed needed.

High-Fat Diets. Some neoplasms, e.g., breast cancer [26], have been associated with high-fat (particularly from animal food sources) dietary patterns. Among the proposed mechanisms contributing to this phenomenon are: a) fat intake may increase endogenous estrogen concentrations, b) saturated fat may increase the risk of breast cancer by enhancing insulin resistance, c) the generation of eicosanoids, from fatty acids, as well as lipid peroxidation may be involved in the modulation of genes associated with mammary carcinogenesis [27-29]. However, fat consumption has not been proven to be associated with many other types of cancer; for example, regarding prostate cancer, studies have not found a relation between the intake of total, saturated, monounsaturated or polyunsaturated and the risk of prostate cancer [8, 30].

Low-Fiber Diet. Dietary fiber intake has been associated with a reduction in the risk of colorectal cancer and adenoma, thus a low-fiber diet has been associated with an increased risk of developing these conditions. Several studies have focused on this association, including two meta-analysis that conclude that dietary fiber intake is inversely associated with the risk of colorectal adenomas and cancer: fiber has shown to reduce the risk of developing colorectal cancer by 10% for each 10g/day of fiber intake. Conversely, low dietary fiber intake (<10g/day) was associated with an 18% increased risk for colorectal cancer [31-33]. Some possible mechanisms through which fiber may reduce such cancer risk include an increase in stool bulk, dilution of fecal carcinogens within colonic lumen, decreased intestinal transit time, as well as production of short chain fatty acids by bacterial fermentation, which increase beneficial gut microbiota and induce differentiation, arrest growth, and cause apoptosis within the gastrointestinal tract [31, 32, 34].

Another example is breast cancer: currently two meta-analyses have found an inverse association between soluble fiber intake and breast cancer risk; further, when dose-response analysis was performed, results revealed that breast cancer risk is significantly decreased in 7% for every 10 g/day increase in dietary fiber. This phenomena may be due to several mechanisms, e.g., dietary fiber may attenuate estrogen blood levels as a result of decreased reabsorption of those hormones (normally, conjugated estrogens are excreted within the bile and may be further reabsorbed at the intestine; however, fiber may bind to such estrogens hence preventing them from entering enterohepatic circulation, i.e., being reabsorbed). Furthermore, soluble fiber delays gastric emptying thus slows glucose absorption and attenuates postprandial hyperglycemia and consequent hyperinsulinemia, which has been proposed to be a risk for breast cancer [35].

Finally, as to prostate cancer and dietary fiber intake, studies have shown conflicting evidence, ranging from a lack of association to an inverse correlation. The effect exerted by fiber can be explained through several mechanisms, including the anti-inflammatory effect of short chain fatty acids provided by fermentation of dietary fiber by the colonic microbiota, as well as an improvement in insulin resistance through a decreased carbohydrate absorption rate [36].

Physical Activity

Research suggests that physical activity (PA) reduces the risk of developing cancer, helps cancer survivors to recover from the treatment, improves long-term health and could reduce the risk or recurrence [37]. In contrast, a sedentary lifestyle has been associated with a wide range of chronic diseases, including cancer and, within the latter, the association is particularly strong breast, colorectal, endometrial, and prostate neoplasms [38].

In addition to the fact that PA is negatively correlated to overweight and obesity thus reduce the inherent cancer risk of such conditions -as discussed in the next section-, the practice of exercise increases the expression and activity of cellular growth and proliferation participating molecules, including sirtuins (SIRTs), hence play an important role in the prevention. SIRTs are a family of NAD+ dependent histone deacetylases which are activated by stress -in this case, manifested as energy shortage from utilization during PA- and have key functions such as cellular defense and repairing activities. SIRT1 is localized in nucleus and cytosol and modulates, among others, neurodegeneration, cell death, gene expression and tumorigenesis. Within the cytosol, SIRT2 is involved in gene expression regulation, cell cycle regulation, DNA damage response, neurodegeneration and cancer. In the mitochondrial inner membrane, SIRT3 participates in the cellular response to oxidative stress, cell death, and tumor suppression positively influencing genomic stability. SIRT6 is involved in DNA repair and genome stability [39]. Moreover SIRT1 modulates levels of the enzyme Suv39H1, which is involved in the maintaining of the structure of heterochromatin during the response to the oxidative stress. This implies an increase in the rate of renewal of heterochromatin, which implies greater protection of the genome [40].

Nutritional Status

Obesity results from an imbalance between the two aforementioned lifestyle actors: excessive and inadequate diet plus insufficient physical activity. The World Health Organization (WHO) defines obesity as a chronic disease characterized by the presence of excessive fat mass to a level that may impair health. It is widely recognized that such condition is a leading risk for worldwide mortality as it is frequently associated with other diseases (i.e., comorbidities), commonly cardiometabolic alterations -e.g., type 2 diabetes mellitus, dyslipidemias, and coronary disease, among others- but also various malignancies (e.g., ovarian, esophageal, breast, large bowel, pancreatic, lymphomas, etc.) have been attributed to obesity [41, 42]. However, the links between nutritional status and the risk of cancer are numerous, intricate, and frequently interrelated, and so they are not yet fully elucidated. In the following lines, we will briefly mention some of these pathways.

Adipose tissue is now recognized as a metabolically active organ that, when in excess, it promotes macrophage infiltration and thus the release of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFα). Among other deleterious effects, the latter ultimately leads to insulin resistance (IR) [43, 44] which, in turn, increases pancreatic secretion of the hormone, resulting in hyperinsulinemia. Some studies have reported the association between increased insulinemia and the risk of developing several cancers (e.g., pancreatic, colon, prostate, breast, renal, endometrial). This epidemiologic phenomenon may be explained by the fact that insulin binding to either its own receptor or to the insulin-like growth factor (IGF) receptor, activates signaling cascades (e.g., the mitogen-activated protein kinase -MAPK- pathway) that culminates in mitogenic activity and anti-apoptotic mechanisms thus may potentiate cancer cells proliferation and tumor progression [45-47]. In fact, within the preclinical scenario, blocking such receptors and/or attenuating hyperinsulinemia has